You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers at the University of Copenhagen used mass spectrometry to analyze dental plaque from 21 individuals recovered from a medieval Danish gravesite.
A number of experts have questioned the clinical validity underlying Interleukin's tests and hope Orig3n will not revive them.
The American Dental Association wants insurers and test manufacturers to show genetic testing is scientifically valid before they're used to determine coverage eligibility.
The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test.
Geneticists and periodontists point to financial conflicts, the lack of genetics knowhow, and regulatory gaps for the availability of a test they say should have never come to market.
The decisions are part of the company's restructuring efforts after it was unable to extend deferral of its debt payment with its senior lender.
The researchers found that patients with periodontitis exhibited patterns of autoantigen hypercitrullination similar to those found in RA patients.
Reanalysis of a prior study found no interaction between Interleukin's PST test and preventive visits or association with the patient outcome of tooth extraction.
Interleukin's revenues fell by more than 50 percent year over year due to a decrease in deferred revenue recognized, but it trimmed its Q4 net loss.
The company raised $5 million in private financing and is borrowing $5 million.
Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.
Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.
Stat News reports some health tech startups are laying off or furloughing workers.
In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.